logo
  

Constantia Flexibles Decides Not To Proceed With IPO

Constantia Flexibles AG, a manufacturer of flexible packaging products, announced that, following intensive investor marketing it has been decided not to proceed with the Initial public offering of Constantia Flexibles as a satisfactory completion of the transaction including a healthy aftermarket development could not be ensured.

In the envisaged IPO, new shares to be issued from a capital increase and existing shares of the selling shareholder, One Equity Partners, would have been placed.

In late-October 2013, Constantia Flexibles Group had announced that it planned an Initial Public Offering before the end of this year.

On 12th November 2013, the company had said it set the price range for its Initial public offering at 19.50 euros - 25.50 euros per share. The offer would comprise up to 5.13 million newly issued and up to 24.08 million shares from the holding of CP Group Holding Cooperatief U.A. In total, 28 million shares should be placed, with an additional up to cover the potential over-allotment, which corresponds to at least 50.0 percent of the share capital (at least 57.5 percent including the over allotment).

The gross proceed from the sales of newly issued shares of 100 million euros would go to the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT